Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 1128320220200020039
Electrolytes & Blood Pressure
2022 Volume.20 No. 2 p.39 ~ p.48
Blood Pressure Control in Patients with Diabetic Kidney Disease
Kim Yae-Ni

Kim Won
Kim Jwa-Kyung
Moon Ju-Young
Park Samel
Fei Jiang
Park Hoon-Suk
Song Sang-Heon
Yoo Tae-Hyun
Lee So-Young
Lee Eun-Young
Kim Chul-Min
Jin Kyu-Bok
Cha Dae-Ryong
Cha Jin-Joo
Han Sang-Youb
Abstract
Diabetic kidney disease (DKD) is the most common cause of end-stage kidney disease.
Blood pressure (BP) control can reduce the risks of cardiovascular (CV) morbidity, mortality, and kidney disease progression. Recently, the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines have suggested the implementation of a more intensive BP control with a target systolic BP (SBP) of <120 mmHg based on the evidence that the CV benefits obtained is outweighed by the kidney injury risk associated with a lower BP target. However, an extremely low BP level may paradoxically aggravate renal function and CV outcomes. Herein, we aimed to review the existing literature regarding optimal BP control using medications for DKD.
KEYWORD
Blood pressure, Diabetes, Kidney, Mortality
FullTexts / Linksout information
Listed journal information